UK markets closed
NIKKEI 225
27,574.43 -111.97 (-0.40%) HANG SENG
19,450.23 +635.41 (+3.38%) CRUDE OIL
71.79 -0.22 (-0.31%) GOLD FUTURES
1,801.30 +3.30 (+0.18%) DOW
33,781.48 +183.56 (+0.55%) BTC-GBP
14,059.51 +242.56 (+1.76%)
Sanofi (SNYNF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 01:51PM EST
| Previous close | 94.43 |
| Open | 94.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 94.90 - 95.05 |
| 52-week range | 73.31 - 114.80 |
| Volume | |
| Avg. volume | 40,449 |
| Market cap | 120.475B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 17.77 |
| EPS (TTM) | 5.35 |
| Earnings date | N/A |
| Forward dividend & yield | 3.52 (3.62%) |
| Ex-dividend date | 06 May 2022 |
| 1y target est | 123.28 |
- Reuters
GSK, Sanofi shares soar as Zantac litigation fears abate
Shares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in early trade following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer. The ruling on Tuesday by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocked out about 50,000 claims in federal court on the basis that they were not backed by sound science. The drugmakers, citing scientific consensus, have repeatedly asserted that Zantac does not cause cancer.
- Investing.com
GSK, Sanofi shares rise after U.S. judge dismisses Zantac cancer link lawsuits
By Scott Kanowsky
- Motley Fool
These 3 Stocks Escaped Tuesday's Market Downdraft
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
© 2022 Yahoo. All rights reserved.
